Introduction
============

Many cardiovascular (CV) events and deaths are tightly associated with vascular structural and functional changes. From a pathophysiological point of view, vascular abnormality includes two forms; one is arteriosclerosis (ARS) and the other is atherosclerosis (ATS). Both are critical, fatal or event-related.[@b1-cia-12-929]

Carotid--femoral pulse wave velocity (cf-PWV) is recognized as a gold standard for the assessment of patients' arterial stiffness, while carotid plaque detection by ultrasound and measurement of ankle--brachial index (ABI) by the four-limb blood pressure (BP) monitoring are the common methods to detect patients' ATS in routine clinical practice.[@b2-cia-12-929] Several reviews and articles have reported that patients may simultaneously suffer from ARS and ATS, and these two vascular disorders were tightly linked.[@b3-cia-12-929]--[@b6-cia-12-929] For instance, a large population study with 3,000 elderly subjects aged 60--101 years reported that arterial stiffness was intensively associated with ATS (*P* for trend \<0.01).[@b7-cia-12-929] Moreover, Huynh et al[@b8-cia-12-929] proposed that arterial stiffening may affect endothelial cells in the vessel wall with aging and promote atherogenesis. In addition, Demer suggested a relationship between functional stiffening and ATS progression.[@b9-cia-12-929] Therefore, it seems that ARS and ATS may commonly coexist in patients with cardiovascular diseases (CVD). Several previous studies have investigated the associations of ARS or ATS with some target organ damage (TOD).[@b10-cia-12-929]--[@b13-cia-12-929] However, whether the combination of ARS and ATS would lead to a worsening prognosis or severe TOD remains unclear. Herein, we aimed to investigate the association of ARS and/or ATS with hypertensive TOD, within a framework of CV risk assessment in a community-dwelling elderly cohort.

Methods
=======

Study population
----------------

The Northern Shanghai Study (NSS) is a community- dwelling prospective study. From June 2014 to August 2015, 1,721 residents were invited, of whom 1,599 (92.9%) participants were enrolled. All residents were included if they were, 1) aged 65 years or more; 2) local residents from urban communities in the north of Shanghai, and 3) available for long-term follow-up. Exclusion criteria were as follows: 1) severe cardiac disease (New York Heart Association IV) or end-stage renal disease (chronic kidney disease \>4); 2) malignant tumor with life expectancy \<5 years, and 3) stroke history within 3 months. The NSS was conducted and financially supported by the Shanghai municipal government (Grant ID, 2013ZYJB0902) and had the approval of Shanghai Tenth People's Hospital Institutional Review Board. Written informed consent was obtained from all participants.

Measurement of social, clinical and biological parameters
---------------------------------------------------------

Every participant was required to answer a questionnaire containing information such as gender, age, weight and height, smoking habits, family history of premature CVD, history of diabetes mellitus/hypertension/cardio-cerebrovascular diseases/renal diseases and usage of medications.

Venous blood samples and urine samples were obtained from fasting participants in the morning. Biological markers, including plasma low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, plasma creatinine (PCr) and urinary microalbumin and creatinine, were assayed by standard methods in the Department of Laboratory Medicine of Shanghai Tenth People's Hospital. Fasting plasma glucose was measured by the glucose oxidase method. Estimated glomerular filtration rate (eGFR) was calculated by the modified MDRD (modification of diet in renal disease) formula for Chinese as follows: eGFR (mL/min/1.73 m^2^) =175× PCr^−1.234^ × age^−0.179^ (women ×0.79).[@b14-cia-12-929] Urinary microalbumin divided by urinary creatinine was defined as urinary albumin--creatinine ratio (UACR).

Measurement of BP, ABI and PWV
------------------------------

BP of each participant was measured three times in the morning using an electronic device, by specialized physicians, with at least 10 minutes' rest each time in a sitting position. The recorded BP value was calculated by the average of the three BP readings.

Bilateral brachial and ankle BPs were simultaneously and automatically measured to calculate ABI (the ratio of brachial systolic BP and ankle systolic BP) using the VP1000 system (Omron, Tokyo, Japan).

Cf-PWV was evaluated by one physician (who did not perform the ultrasound examination) using applanation tonometry (SphygmoCor; AtCor Medical, Sydney, Australia), according to the European Expert Consensus on Arterial Stiffness.[@b15-cia-12-929] Two pressure waves were recorded transcutaneously in the right carotid and right femoral arteries. PWV was identified as the foot-to-foot velocity. Pulse transit time for each artery was automatically calculated via electrocardiogram (ECG) data. The traveling distance covered by the pulse wave between the two recording sites was measured over the body surface. cf-PWV was calculated by traveling distance divided by traveling time, and an operator index \>80% indicated a high-quality measurement.

Ultrasonography
---------------

Ultrasound examinations were performed by a single experienced sonographer using the MyLab 30 Gold CV system (ESAOTE SpA, Genoa, Italy), with a 7.5 MHz probe. The presence or absence of plaque in the right carotid artery was assessed by evaluating the ultrasonographic images. No attempt was made to record the quantity and size of the lesions. "Plaque =0" referred to the absence of plaque, while "plaque =1" referred to the presence of plaque.

M-mode or two-dimensional echocardiography was used to assess the measurement of left ventricular end-diastolic diameter (LVEDd), interventricular septal diameter (IVSd), posterior wall thickness at end-diastole diameter (PWTd) and left ventricular end-systolic diameter (LVESd) from the parasternal view,[@b16-cia-12-929],[@b17-cia-12-929] and then left ventricular mass (LVM) was calculated through those parameters using related formulas.[@b18-cia-12-929] Left ventricular mass index (LVMI) was assessed by LVM divided by body surface area (BSA).[@b19-cia-12-929] LVM (g) =0.8×{1.04× \[(LVEDd + PWTd + IVSd)[@b3-cia-12-929] − (LVEDd)[@b3-cia-12-929] +0.6 and LVMI (g/m^2^) = LVM/BSA. Left ventricular ejection fraction (LVEF) was calculated through left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV) estimates, using the following formula: LVEF = (EDV − ESV)/EDV.[@b20-cia-12-929] Peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity (E/Ea) was performed by continual wave Doppler in the four-chamber view and was calculated for the evaluation of LV diastolic function. The abovementioned measurements were made according to the guidelines laid out by the American Society of Echocardiography (ASE).[@b16-cia-12-929]

Definition of ARS and ATS
-------------------------

ARS was defined as cf-PWV \>12 m/s, while ABI \<0.9 or the presence of carotid plaque represented ATS.[@b2-cia-12-929],[@b21-cia-12-929],[@b22-cia-12-929]

Definition of hypertensive TOD
------------------------------

Asymptomatic hypertensive TOD investigated in this study included cardiac and renal TOD. Left ventricular hypertrophy (LVH) was defined as LVMI ≥115 g/m^2^ (male) or LVMI ≥95 g/m^2^ (female). Left ventricular diastolic dysfunction (LVDD) was assessed by E/Ea and other evidence of abnormal left ventricular relaxing and filling, such as enlarged left atrial volume and increased LVM.[@b23-cia-12-929] Specifically, diastolic dysfunction was defined as E/Ea ≥15 or 15\> E/Ea \>8 with the following (LVMI \>149 g/m^2^ \[male\] or LVMI ≥122 g/m^2^ \[female\]).[@b23-cia-12-929],[@b24-cia-12-929] Renal TOD was defined as microalbuminuria (MAU) (UACR \>30) and renal dysfunction (RD) (creatinine clearance rate \<60 mL/min/1.73 m^2^).

Statistical analysis
--------------------

Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were presented as numbers with the percentage in parentheses. Participants were divided into three groups according to the participants' presence of ARS and/or ATS, such as normal (without ARS and ATS), ARS/ATS (with either ARS or ATS) and ARS+ATS (with both ARS and ATS). The association of conventional CV risk factors with participants with or without ARS and/or ATS (normal, ARS/ATS, ARS+ATS) was assessed by general linear model for variance analysis, such as age, gender, body mass index (BMI), smoking status, systolic BP, fasting plasma glucose and LDL cholesterol. Three models were set with different adjustments: Model 1 (without adjustment), Model 2 (with adjustment for age and gender) and Model 3 (with adjustment for age, gender, BMI, smoking status, systolic BP and blood glucose). The comparisons of all parameters of asymptomatic TOD among the three groups were carried out using variance analysis, including LVMI, E/Ea, UACR and eGFR. Furthermore, multivariate logistic regressions were conducted to investigate the association of hypertensive TOD with ARS/ATS and ARS+ATS. Statistical analysis was performed using standard procedures from the Statistical Analysis System (SAS), version 9.3 (SAS Institute, Cary, NC, USA). *P*\<0.05 was considered statistically significant.

Results
=======

Participants
------------

Characteristics of participants by gender are presented in [Table 1](#t1-cia-12-929){ref-type="table"}, including conventional CV risk factors, asymptomatic hypertensive TOD and diseases and treatment. The 1,599 participants included 711 (44.5%) men, 312 (19.5%) diabetics and 843 (52.7%) hypertensives, of whom 799 (93.9%) were taking antihypertensive agents. Men, compared with women, had lower total cholesterol (4.92±0.99 vs 5.46±0.96 mmol/L, *P*\<0.001), triglycerides (1.54±0.85 vs 1.66±1.00 mmol/L, *P*=0.008), HDL cholesterol (1.28±0.33 vs 1.46±0.36 mmol/L, *P*\<0.001), LDL cholesterol (3.04±0.85 vs 3.33±0.83 mmol/L, *P*\<0.001), pulse pressure (54.4±14.0 vs 56.2±16.1 mmHg, *P*=0.02), eGFR (88.3±20.0 vs 95.8±22.5 mL/min/1.73 m^2^, *P*\<0.001), E/Ea (9.29±3.51 vs 10.11±3.71, *P*\<0.001) but they had significantly more smokers (49.4% vs 1.7%, *P*\<0.001) and greater incidence of carotid plaque (54.3% vs 48.9%, *P*=0.03).

Association of ARS and/or ATS with CV risk factors
--------------------------------------------------

Conventional CV risk factors, including age, gender, BMI, smoking status, systolic BP, fasting plasma glucose and LDL cholesterol, were put into a variance analysis model to investigate their association with ARS and ATS. As shown in [Table 2](#t2-cia-12-929){ref-type="table"}, age, BMI, smoking status, systolic BP and fasting plasma glucose were significantly different between participants with or without ARS and/or ATS (*P*≤0.02).

Association of asymptomatic hypertensive TOD with ARSand/or ATS
---------------------------------------------------------------

In the variance analysis of ARS and ATS with hypertensive TOD, all parameters of asymptomatic TOD (*P*\<0.02) were significantly different among the three groups, except LVEF (*P*=0.11; [Table 3](#t3-cia-12-929){ref-type="table"}, Model 1) and UACR (*P*=0.16; [Table 3](#t3-cia-12-929){ref-type="table"}, Model 1). Of note, in Model 3 with full adjustment, only E/Ea significantly differed among the three groups (*P*=0.02; [Table 3](#t3-cia-12-929){ref-type="table"}, Model 3). Moreover, E/Ea was significantly different between ARS/ATS and normal (*P*=0.045), while there was no significant difference between ARS+ATS and normal (*P*=0.28). As LVEF was not significantly different among these groups (*P*=0.10; [Table 3](#t3-cia-12-929){ref-type="table"}, Model 3), we did not adjust for LVEF in the subsequent multivariate logistic regressions.

As shown in [Table 4](#t4-cia-12-929){ref-type="table"}, with similar adjustment strategy analyzed by the multiple logistic regression model, most asymptomatic TOD was significantly associated with ARS/ATS and ARS+ATS, but only ARS/ATS was significantly associated with LVDD in the full adjustment model, with an odds ratio (OR) =1.50 (95% confidence interval \[CI\] 1.07--2.09; [Figure 1](#f1-cia-12-929){ref-type="fig"}).

Finally, when ARS and ATS were separately put in the logistic regression model, in the full adjustment model, LVDD was significantly associated with ATS (OR 1.55; 95% CI 1.11--2.17, *P*=0.01) but not with ARS (OR 0.99; 95% CI 0.45--2.18, *P*=0.99) ([Table 5](#t5-cia-12-929){ref-type="table"}).

Discussion
==========

There are two major findings in this study. First, age, BMI, smoking status, systolic BP and fasting plasma glucose were significantly different between participants with or without ARS and/or ATS. Second, among hypertensive TOD, LVDD as measured by E/Ea was significantly associated with ATS but not with ARS, and the proportion of patients with LVDD was not significantly different despite the presence of both ATS and ARS, when compared to patients with ATS alone in the community-dwelling elderly Chinese.

ARS and ATS are pathologically different and possess different clinical manifestations.[@b25-cia-12-929],[@b26-cia-12-929] ARS is a degenerative process of the media of elastic arteries and the calcification in arterial wall under the effect of aging and risk factors.[@b27-cia-12-929] The mechanism of ARS is the chronic vascular inflammation derived from mitochondrial oxidative stress in smooth muscle cells.[@b28-cia-12-929] It would only cause stiffness and thickness of the arterial wall but without luminal stenosis and syndromes of tissue/organ ischemia.[@b4-cia-12-929],[@b29-cia-12-929] However, ATS is the underlying cause of most ischemic diseases, such as myocardial infarction and ischemic stroke. Pathologically, ATS is a chronic inflammatory response to the accumulation of lipid in the artery wall and causes intimal plaques and stenosis in arteries. Disruption of atherosclerotic plaques will trigger the formation of a thrombus and subsequently cause acute ischemia of the end organ. Although its prevalence is also age-related, the major risk factor that promotes the development of ATS is high level of cholesterol.[@b30-cia-12-929],[@b31-cia-12-929] As ARS and ATS are the two most common types of modifications in vascular structure and they are prevalent in the elderly, it is meaningful to investigate their respective and combined association with TOD. In this study, we found that, among cardiac and renal TOD, only LVDD was significantly associated with ATS but not with ARS. The association of LVDD with different indicators of arterial stiffness and ATS has been previously reported. Some previous studies indicated that arterial stiffness, assessed by the cardio-ankle vascular index (CAVI), was significantly correlated with LVDD.[@b32-cia-12-929]--[@b34-cia-12-929] Some other reports discussed a strong association between LVDD and arterial stiffness assessed by PWV.[@b35-cia-12-929],[@b36-cia-12-929] Albu et al[@b37-cia-12-929] conducted an investigation into 96 postmenopausal women and proposed that aortic PWV was an independent predictor of LVDD (OR 2.15, 95% CI 1.39--3.31, *P*=0.0006), while carotid plaque score did not show correlation with LVDD after adjustment. However, some investigators reported that the presence of carotid ATS was significantly related to LVDD,[@b38-cia-12-929]--[@b40-cia-12-929] which was in accordance with our finding. Other studies concerning arterial stiffness were not consistent with our results. Several possible reasons may probably contribute to the discrepancies. First, arterial stiffness in those studies was assessed mainly by the CAVI but not by PWV. Although the CAVI, as a new index of arterial stiffness, was suggested to be superior to PWV due to its BP independence, different indicators in arterial stiffness may lead to miscellaneous results. Second, those studies were mainly conducted on patients with high CV risk or with coronary artery disease (CAD) or heart failure (HF) or other established cardiac diseases, while we focused on the community-dwelling elderly population. The last point may be the most important. Since participants in those studies may suffer both ATS and ARS, the observed significant association between arterial stiffness of those participants and LVDD would be due to ATS, and the association was therefore overestimated. However, in our analysis, ARS and ATS were separately investigated.

Nevertheless, there are limited data concerning the mutual association of ARS and ATS with LVDD. In our study, we found that their combination did not actually worsen patients' LV diastolic function. This finding seems to conflict with the finding that LVDD was significantly associated with ATS. Of note, since our results were double checked by the variance analysis and multivariate logistic regression models and with sufficient adjustments, we believe that our findings are reliable. The possible explanation may lie in the fact that arterial stiffening is very prevalent in the elderly. Therefore, PWV, as influenced by biological aging, become less significant in predicting events and deaths in the geriatric population.[@b41-cia-12-929]--[@b43-cia-12-929] Further investigations focusing on the younger population or middle-age population are warranted to confirm the present finding.

Since hypertensive TOD is of great importance and is recognized as the intermediate outcome connecting CV risk factors and CV events and mortality, it is meaningful to investigate some potential markers to screen TOD. LVDD is considered as one of the major causes of HF with preserved ejection fraction. Our finding indicated that, in accordance with other studies, LVDD was tightly associated with ATS. Therefore, the presence of ATS, even in the elderly, may indicate the high risk for the development of LVDD and early and intensified intervention may be needed in preventing future heart failure with preserved ejection fraction.

Limitations
===========

Findings of this study need to be interpreted within the context of its limitations. First, we could not fully adjust for the potential influence from the various medications on cf-PWVs, ABI and carotid plaque, etc., such as antihypertensive, antidiabetic and anti-hyperlipidemic drugs. Second, as a cross-sectional analysis, this study cannot tell the cause--effect relationship between ATS and LVDD.

Conclusion
==========

In the community-dwelling elderly Chinese, among hypertensive TOD, LVDD was significantly associated with ATS but not with ARS. The proportion of patients with LVDD was not significantly different despite the presence of both ATS and ARS, when compared to patients with ATS alone.
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###### 

Characteristics of participants by gender

  Characteristics                          Overall (n=1,599)   Men (n=711)   Women (n=888)   *P*-value
  ---------------------------------------- ------------------- ------------- --------------- -----------
  CV risk factors                                                                            
   Age, years                              72.6±6.0            72.7±5.9      72.6±6.1        0.96
   Smoker, n (%)                           366 (22.9)          351 (49.4)    15 (1.7)        \<0.001
   BMI, kg/m^2^                            23.9±3.5            23.9±3.3      23.9±3.6        0.92
   Fasting plasma glucose, mmol/L          5.69±1.70           5.72±1.67     5.67±1.73       0.55
   Total cholesterol, mmol/L               5.22±1.01           4.92±0.99     5.46±0.96       \<0.001
   Triglycerides, mmol/L                   1.61±0.93           1.54±0.85     1.66±1.00       0.008
   HDL cholesterol, mmol/L                 1.38±0.36           1.28±0.33     1.46±0.36       \<0.001
   LDL cholesterol, mmol/L                 3.20±0.85           3.04±0.85     3.33±0.83       \<0.001
   Systolic BP, mmHg                       134.3±17.7          134.3±16.8    134.3±18.4      0.95
   Diastolic BP, mmHg                      78.9±9.1            80.0±9.2      78.1±9.0        \<0.001
  Asymptomatic hypertensive TOD                                                              
   Pulse pressure, mmHg                    55.4±15.2           54.4±14.0     56.2±16.1       0.02
   LVMI, g/m^2^                            90.0±28.6           90.5±28.8     89.6±28.4       0.54
   Plaque in right carotid artery, n (%)   817 (51.3)          384 (54.3)    433 (48.9)      0.03
   cf-PWV, m/s                             9.42±2.31           9.36±2.42     9.48±2.21       0.32
   eGFR, mL/min/1.73 m^2^                  92.4±21.7           88.3±20.0     95.8±22.5       \<0.001
   UACR, mg/g                              54.9±181.6          51.1±108.3    58.0±224.4      0.45
   E/Ea                                    9.75±3.64           9.29±3.51     10.11±3.71      \<0.001
   Left ABI, g/m^2^                        1.03±0.13           1.04±0.13     1.03±0.13       0.60
   LVEF                                    0.58±0.19           0.59±0.10     0.58±0.23       0.23
  Diseases and treatment                                                                     
   Hypertension, n (%)                     843 (52.7)          385 (54.2)    458 (51.6)      0.31
   Treated hypertension, n (%)             799 (93.9)          363 (93.1)    436 (94.6)      0.36
   CVD, n (%)                              549 (34.3)          231 (32.5)    318 (35.8)      0.16
   Anti-platelet treatment, n (%)          424 (26.6)          204 (28.8)    220 (24.8)      0.07
   Statin treatment, n (%)                 259 (16.2)          102 (14.4)    157 (17.7)      0.08
   Stroke or TIA, n (%)                    318 (19.9)          130 (18.3)    188 (21.2)      0.15
   Renal disease, n (%)                    132 (8.3)           55 (7.8)      77 (8.7)        0.52
   Diabetes, n (%)                         312 (19.5)          137 (19.3)    175 (19.7)      0.83
   Antidiabetic treatment, n (%)           262 (37.8)          115 (37.7)    147 (37.8)      0.98
   Insulin treatment, n (%)                51 (7.4)            22 (7.2)      29 (7.5)        0.90

**Notes:** Data presented as mean ± standard deviation unless stated otherwise. Student's *t*-test and chi-square test were conducted to compare the differences between men and women for quantitative and qualitative variables, respectively. eGFR was calculated using the modified MDRD formula for Chinese. E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity.

**Abbreviations:** ABI, ankle--brachial index; BMI, body mass index; BP, blood pressure; cf-PWV, carotid--femoral pulse wave velocity; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MDRD, modification of diet in renal disease; SD, standard deviation; TIA, transient ischemic attack; TOD, target organ damage; UACR, urinary albumin--creatinine ratio.

###### 

Association of CV risk factors with ARS and/or ATS

  CV risk factors                  Normal (n=622)   ARS/ATS (n=792)   ARS+ATS (n=128)   *P*-value
  -------------------------------- ---------------- ----------------- ----------------- -----------
  Age, years                       71.2±5.11        73.0±6.17         76.6±6.35         \<0.001
  Gender (male), n (%)             256 (41.2)       368 (46.5)        53 (41.4)         0.11
  BMI                              23.6±3.52        24.0±3.44         24.4±3.21         0.02
  Smoker, n (%)                    114 (18.3)       210 (26.5)        28 (21.9)         0.001
  Systolic BP, mmHg                131.4±16.7       135.2±17.7        145.2±18.6        \<0.001
  Fasting plasma glucose, mmol/L   5.56±1.61        5.69±1.74         6.39±1.88         \<0.001
  LDL cholesterol, mmol/L          3.16±0.78        3.22±0.89         3.28±0.91         0.24

**Notes:** Data presented as mean ± standard deviation unless stated otherwise. Variance analysis was done to investigate the association of CV risk factors with ARS and/or ATS; ARS/ATS, with either ARS or ATS; ARS+ATS, with both ARS and ATS.

**Abbreviations:** ARS, arteriosclerosis; ATS, atherosclerosis; BMI, body mass index; BP, blood pressure; CV, cardiovascular; LDL, low-density lipoprotein.

###### 

Association of ARS and/or ATS with parameters of asymptomatic hypertensive TOD analyzed by variance analyses with different adjustments

  Asymptomatic hypertensive TOD   Normal (n=622)   ARS/ATS (n=792)   ARS+ATS (n=128)   Model 1, *P*-value   Model 2, *P*-value′   Model 3, *P*-value″
  ------------------------------- ---------------- ----------------- ----------------- -------------------- --------------------- ---------------------
  LVMI, g/m^2^                    86.2±26.6        91.4±29.7         96.8±25.0         \<0.001              0.004                 0.07
  E/Ea                            9.4±3.31         10.0±3.91         9.8±3.34          0.02                 0.02                  0.02
  LVEF                            0.57±0.27        0.59±0.10         0.57±0.11         0.11                 0.12                  0.10
  UACR, mg/g                      45.8±85.0        56.2±235.3        79.2±147.9        0.16                 0.34                  0.76
  eGFR, mL/min/1.73 m^2^          94.8±20.1        92.3±22.5         85.9±22.8         \<0.001              0.34                  0.08

**Notes:** Data presented as mean ± standard deviation unless stated otherwise. Variance analyses with different adjustments were conducted to investigate the association of ARS and/or ATS with parameters of asymptomatic hypertensive TOD. E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity; Model 1: without adjustment; Model 2: with adjustment for age and gender; Model 3: with adjustment for age, gender, BMI, smoking status, systolic BP and blood glucose. ARS/ATS, with either ARS or ATS; ARS+ATS, with both ARS and ATS.

**Abbreviations:** ARS, arteriosclerosis; ATS, atherosclerosis; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; TOD, target organ damage; UACR, urinary albumin--creatinine ratio.

###### 

Association of ARS and/or ATS with parameters of asymptomatic hypertensive TOD analyzed by multivariate logistic regressions with different adjustments

  TOD                  Model 1 OR (95% CI)   Model 2 OR (95% CI)   Model 3 OR (95% CI)
  -------------------- --------------------- --------------------- ---------------------
  LVH                                                              
   ARS/ATS vs normal   1.21 (0.95--1.53)     1.21 (0.95--1.55)     1.18 (0.92--1.52)
   ARS+ATS vs normal   1.93 (1.30--2.88)     1.71 (1.12--2.61)     1.49 (0.95--2.33)
  LVDD                                                             
   ARS/ATS vs normal   1.63 (1.19--2.24)     1.63 (1.18--2.25)     1.50 (1.07--2.09)
   ARS+ATS vs normal   1.76 (1.03--3.00)     1.47 (0.85--2.57)     1.06 (0.59--1.90)
  MAU                                                              
   ARS/ATS vs normal   1.08 (0.87--1.34)     1.03 (0.83--1.28)     0.93 (0.74--1.17)
   ARS+ATS vs normal   1.99 (1.35--2.94)     1.63 (1.09--2.44)     1.18 (0.77--1.81)
  RD                                                               
   ARS/ATS vs normal   2.03 (1.26--3.29)     1.63 (0.99--2.68)     1.63 (0.99--2.70)
   ARS+ATS vs normal   2.97 (1.48--5.97)     1.55 (0.74--3.23)     1.60 (0.75--3.40)

**Notes:** Multivariate logistic regressions with different adjustments were conducted to investigate the association of ARS and/or ATS with asymptomatic hypertensive TOD. Model 1: without adjustment; Model 2: with adjustment for age and gender; Model 3: with adjustment for age, gender, BMI, smoking status, systolic BP and blood glucose. ARS/ATS, with either ARS or ATS; ARS+ATS, with both ARS and ATS.

**Abbreviations:** ARS, arteriosclerosis; ATS, atherosclerosis; CI, confidence interval; LVH, left ventricular hypertrophy; LVDD, left ventricular diastolic dysfunction; MAU, microscale albuminuria; OR, odds ratio; RD, renal dysfunction; TOD, target organ damage.

###### 

Association of ARS and ATS with LVDD analyzed by multivariate logistic regressions with different adjustments

  TOD                  Model 1 OR (95% CI)   Model 2 OR (95% CI)   Model 3 OR (95% CI)
  -------------------- --------------------- --------------------- ---------------------
  LVDD                                                             
   ARS vs normal       1.53 (0.72--3.24)     1.32 (0.61--2.84)     0.99 (0.45--2.18)
   ATS vs normal       1.64 (1.19--2.26)     1.65 (1.19--2.29)     1.55 (1.11--2.17)
   ARS+ATS vs normal   1.76 (1.03--3.00)     1.47 (0.84--2.56)     1.04 (0.58--1.88)

**Notes:** Multivariate logistic regressions with different adjustments were conducted to investigate the respective association of ARS and ATS with LVDD. Model 1: without adjustment; Model 2: with adjustment for age and gender; Model 3: with adjustment for age, gender, BMI, smoking status, systolic BP and blood glucose. ARS+ATS, with both ARS and ATS.

**Abbreviations:** ARS, arteriosclerosis; ATS, atherosclerosis; BMI, body mass index; BP, blood pressure; CI, confidence interval; OR, odds ratio; LVDD, left ventricular diastolic dysfunction; TOD, target organ damage.
